scholarly journals Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins

Vaccine ◽  
2014 ◽  
Vol 32 (22) ◽  
pp. 2637-2644 ◽  
Author(s):  
Blair L. DeBuysscher ◽  
Dana Scott ◽  
Andrea Marzi ◽  
Joseph Prescott ◽  
Heinz Feldmann
Keyword(s):  
Single Dose ◽  
Nipah Virus ◽  
Complete Protection ◽  
Surface Glycoproteins

scholarly journals Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus

npj Vaccines ◽  
2019 ◽  
Vol 4 (1) ◽  
Author(s):  
Fangfang Dong ◽  
Dandan Li ◽  
Dan Wen ◽  
Suhua Li ◽  
Chaoyue Zhao ◽  
...  
Keyword(s):  
Single Dose ◽  
Complete Protection ◽  
Severe Fever

scholarly journals Single-dose replicon particle vaccine provides complete protection against Crimean-Congo hemorrhagic fever virus in mice

2019 ◽  
Vol 8 (1) ◽  
pp. 575-578 ◽  
Author(s):  
Florine E. M. Scholte ◽  
Jessica R. Spengler ◽  
Stephen R. Welch ◽  
Jessica R. Harmon ◽  
JoAnn D. Coleman-McCray ◽  
...  
Keyword(s):  
Single Dose ◽  
Hemorrhagic Fever ◽  
Fever Virus ◽  
Complete Protection ◽  
Crimean Congo Hemorrhagic Fever ◽  
Hemorrhagic Fever Virus ◽  
Replicon Particle

scholarly journals Evaluation of a Single-Dose Nucleoside-Modified Messenger RNA Vaccine Encoding Hendra Virus-Soluble Glycoprotein Against Lethal Nipah virus Challenge in Syrian Hamsters

2019 ◽  
Vol 221 (Supplement_4) ◽  
pp. S493-S498 ◽  
Author(s):  
Michael K Lo ◽  
Jessica R Spengler ◽  
Stephen R Welch ◽  
Jessica R Harmon ◽  
JoAnn D Coleman-McCray ◽  
...  
Keyword(s):  
Single Dose ◽  
Immune Responses ◽  
Messenger Rna ◽  
Nipah Virus ◽  
Hendra Virus ◽  
Highly Pathogenic ◽  
Syrian Hamsters ◽  
Virus Challenge ◽  
Pathogenic Viruses ◽  
Rna Vaccine

Abstract In the absence of approved vaccines and therapeutics for use in humans, Nipah virus (NiV) continues to cause fatal outbreaks of encephalitis and respiratory disease in Bangladesh and India on a near-annual basis. We determined that a single dose of a lipid nanoparticle nucleoside-modified messenger RNA vaccine encoding the soluble Hendra virus glycoprotein protected up to 70% of Syrian hamsters from lethal NiV challenge, despite animals having suboptimally primed immune responses before challenge. These data provide a foundation from which to optimize future messenger RNA vaccination studies against NiV and other highly pathogenic viruses.

scholarly journals A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters

2019 ◽  
Vol 13 (6) ◽  
pp. e0007462 ◽  
Author(s):  
Neeltje van Doremalen ◽  
Teresa Lambe ◽  
Sarah Sebastian ◽  
Trenton Bushmaker ◽  
Robert Fischer ◽  
...  
Keyword(s):  
Single Dose ◽  
Complete Protection ◽  
Golden Hamsters ◽  
Syrian Golden Hamsters ◽  
Vectored Vaccine

The optimal dose period of indisetron tablets for preventing chemotherapy-induced nausea and vomiting (CINV) induced by mFOLFOX6: An exploratory trial HGCSG0703.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 589-589
Author(s):  
S. Yuki ◽  
H. Nakatsumi ◽  
M. Tateyama ◽  
Y. Uehata ◽  
M. Kudo ◽  
...  
Keyword(s):  
Single Dose ◽  
Rescue Therapy ◽  
Optimal Dose ◽  
Nausea And Vomiting ◽  
Complete Protection ◽  
Chi Square ◽  
Dose Period ◽  
Chi Square Test ◽  
Group A ◽  
Group B

589 Background: Indisetron is a 5-HT3 receptor antagonist which shows also 5-HT4 antagonistic activity, that had approved in 2004 by Japan's PMDA. There are no recommendations of prophylactic regimens for preventing nausea and vomiting induced by FOLFOX therapy. To explore the optimal dose period of indisetron tablets during mFOLFOX6, we designed the study to compare the antiemetic efficacy and safety of 3-day regimen of indisetron with a single dose regimen. Methods: Advanced colorectal cancer patients who were treated with mFOLFOX6 (+/- bevacizumab) as first-line chemotherapy were enrolled in this study. They were randomly assigned to Group A (3-day of indisetron) or Group B (a single dose of indisetron). Dexamethazone (8mg) was also administered intravenously in both groups before administering of oxaliplatin. The follow-up period was 5 days from the start of chemotherapy. The primary endpoint was complete protection from vomiting, and secondary endpoints were complete protection from nausea, no use of rescue therapy, and severe adverse events. Results: Of 45 patients enrolled in this trial, 42 (93.3%) were assessable. The proportions of patients with complete protection from vomiting were 85.7% in Group A, and 81.0% in Group B (p=1.000; Fisher's exact test). The proportions of patients with complete protection from nausea were 47.6% in each group (p=1.000; chi-square test). The no rescue therapy rates were 66.7% in Group A, and 57.1% in Group B (p=0.525; chi-square test). No severe adverse events were observed in both groups. Conclusions: We suggested that the efficacy of a single dose of indisetron might be equivalent of 3-day regimen for preventing from nausea and vomiting induced by mFOLFOX6. [Table: see text]

scholarly journals Peri-exposure protection against Nipah virus disease using a single-dose recombinant vesicular stomatitis virus-based vaccine

npj Vaccines ◽  
2016 ◽  
Vol 1 (1) ◽  
Author(s):  
Blair L DeBuysscher ◽  
Dana Scott ◽  
Tina Thomas ◽  
Heinz Feldmann ◽  
Joseph Prescott
Keyword(s):  
Single Dose ◽  
Vesicular Stomatitis Virus ◽  
Virus Disease ◽  
Nipah Virus ◽  
Vesicular Stomatitis

Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research.

1989 ◽  
Vol 7 (11) ◽  
pp. 1693-1700 ◽  
Author(s):  
F Roila ◽  
M Tonato ◽  
C Basurto ◽  
M Picciafuoco ◽  
S Bracarda ◽  
...  
Keyword(s):  
Single Dose ◽  
Dose Schedule ◽  
High Dose ◽  
Oncology Group ◽  
Complete Protection ◽  
Double Blind ◽  
Younger Patients ◽  
Multifactorial Analysis ◽  
Significant Difference ◽  
Efficacy Of Treatment

Despite treatment, emesis remains a major problem with cisplatin (CDDP) chemotherapy. Reasons for variability in antiemetic response among patients and in subsequent cycles are largely unknown and toxicity is sometimes severe. We have, therefore, carried out a multicenter, double-blind randomized trial comparing a combination of high-dose metoclopramide (MTC) (1 mg/kg x 4) and methylprednisolone (P) (treatment A) with a shorter but higher single-dose schedule of metoclopramide (3 mg/kg x 2) combined with dexamethasone (DEX) and diphenhydramine (DIP) to prevent extrapyramidal reactions (treatment B). Three hundred sixty-seven consecutive patients treated with various chemotherapy combinations containing CDDP were studied. Complete protection from vomiting/nausea was, at first cycle, 72.5%/79.5% with treatment B and 55.8%/65.1% with treatment A, a statistically significant difference (P less than .002/P less than .005). In subsequent cycles, protection from emesis significantly decreased with no difference between the two treatments. Multifactorial analysis shows that women, younger patients, outpatients, and patients who experienced emesis in previous cycles were at higher risk of suffering nausea and/or vomiting. Both regimens were well tolerated, but patients treated with treatment B had significantly less extrapyramidal reactions (1.7%/6.1%, P = .053). Treatment B is preferred due to its greater efficacy and lower incidence of extrapyramidal reactions. Trials on antiemetic therapy should take into account the important variables able to influence the efficacy of treatment. There is still a need for improving prevention of emesis in CDDP-treated patients.

scholarly journals Complete Protection from Papillomavirus Challenge after a Single Vaccination with a Vesicular Stomatitis Virus Vector Expressing High Levels of L1 Protein

2004 ◽  
Vol 78 (6) ◽  
pp. 3196-3199 ◽  
Author(s):  
Anjeanette Roberts ◽  
Jon D. Reuter ◽  
Jean H. Wilson ◽  
Stuart Baldwin ◽  
John K. Rose
Keyword(s):  
Single Dose ◽  
Vesicular Stomatitis Virus ◽  
Complete Protection ◽  
Downstream Site ◽  
Upstream Site ◽  
Cottontail Rabbit ◽  
Single Vaccination ◽  
Vesicular Stomatitis ◽  
L1 Protein ◽  
Dose Vaccine

ABSTRACT We generated an attenuated, recombinant vesicular stomatitis virus (VSV) expressing high levels of the cottontail rabbit papillomavirus (CRPV) L1 protein from an upstream site in the VSV genome. Rabbits vaccinated once with this VSV-L1 recombinant produced high levels of anti-L1 antibody and were completely protected against papilloma formation after challenge with CRPV. In contrast, animals vaccinated only once with a VSV vector expressing lower levels of L1 from a downstream site in the VSV genome generated lower levels of L1 antibody and demonstrated only incomplete protection from papilloma formation after challenge. We conclude that the level of L1 protein expression is critical in generating complete immunity with a single-dose vaccine.

Sign in / Sign up

Export Citation Format

Share Document